NEW YORK (GenomeWeb) – GenMark Diagnostics said today that it has increased the size of its previously announced public offering to 6,382,978 shares of its common stock price at $11.75 per share.

The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be about $75.0 million.

JP Morgan and Bank of America Merrill Lynch are joint book-running managers for the offering. William Blair, Cowen, and Raymond James are co-managers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.